Wegovy 2.4mg side effects: deciding whether they're manageable for you

The side effects most people encounter at 2.4mg Wegovy

The bulk of the side effects reported with 2.4mg semaglutide fall into two broad categories: gastrointestinal and, less often, general effects like fatigue or headache. Nausea tops the list. It's followed by vomiting, diarrhoea, constipation, reflux, indigestion and burping. Fatigue and dizziness appear too, and some people notice injection-site reactions, mild redness or tenderness where the pen was used.

The reason these effects cluster at the start or after a dose change is that semaglutide slows gastric emptying, food moves through the stomach more slowly, which reduces appetite but can also create a sensation of fullness that tips into nausea. By the time most people reach 2.4mg, they've already titrated through 0.25mg, 0.5mg, 1mg and 1.7mg, each held for roughly four weeks. That slow climb means your system has had months to adapt. Arriving at 2.4mg rarely hits as hard as the very first dose did.

That said, each upward step can bring a brief return of symptoms. A week or two of more noticeable nausea after reaching the maintenance dose is not unusual. Eating smaller portions, choosing lower-fat foods, staying upright after meals and keeping well hydrated are the practical steps most people find helpful, though your prescriber and the Patient Information Leaflet are the right resources for personal guidance. If you're curious how the 2.4mg profile compares to earlier points in the schedule, the 1.7mg side effects page covers the step just before this one, and you can also read about what side effects people commonly notice at the 1mg stage for a broader picture of how the titration tends to unfold.

Side effects that need medical attention, and when to act

Most side effects of Wegovy 2.4mg are uncomfortable rather than dangerous. A few, however, are serious enough that they warrant prompt action rather than waiting to see.

Pancreatitis is infrequent but significant. In January 2026 the MHRA issued a Drug Safety Update specifically highlighting acute pancreatitis as a known risk with GLP-1 medicines: if you develop severe pain in your stomach or abdomen that doesn't ease, especially if it spreads to the back and is accompanied by vomiting, stop the injection and get medical help the same day, don't wait for your next prescriber appointment. Gallbladder problems can also develop, and symptoms there often feel similar: upper-right abdominal pain, sometimes with nausea.

Allergic reactions are rare but can be serious. Swelling of the face or throat, difficulty breathing, or a severe rash needs emergency care. Dehydration from prolonged vomiting or diarrhoea matters too, particularly if you have any kidney condition, persistent gut symptoms that stop you drinking normally should prompt a call to your GP or 111 rather than pushing through. And if you notice a significant low mood or thoughts of self-harm after starting or increasing the dose, speak to a clinician promptly. The NHS semaglutide information page sets out the full side-effect profile clearly, and it's worth reading before or alongside treatment.

Who this decision is harder for: factors that affect tolerability

Most people considering the 2.4mg maintenance dose have already made it through several months of titration, which provides a reasonable signal about how they'll tolerate it. But tolerability isn't a fixed quality. A few factors consistently make GI side effects worse: eating large meals, high-fat foods, alcohol, or eating quickly. People who have an existing history of acid reflux or gastric conditions sometimes find symptoms more pronounced.

The prescribing decision also accounts for contraindications. Wegovy is not recommended during pregnancy, whilst breastfeeding, or for anyone trying to conceive. It is not licensed for under-18s. A history of pancreatitis, medullary thyroid carcinoma or certain other conditions means the prescriber will want to weigh up the picture carefully. These aren't reasons to rule it out automatically, but they are part of the conversation a clinical assessment should cover.

Our clinical team reviews these questions during every consultation, not as a box-ticking formality, but as a genuine assessment of whether the medicine is appropriate for you. Understanding the full dosing schedule can also help frame where 2.4mg fits in the broader journey.

Practical context: how the 2.4mg profile compares across the titration

It's useful to know that the side-effect pattern at 2.4mg is not categorically different from what people experience at lower doses, it's more a matter of degree, and for many patients the 2.4mg step is actually less disruptive than the jump from 0.25mg to 0.5mg, simply because adaptation has had more time to happen. Those who want a clear reference point on that earlier transition can find a detailed breakdown on the Wegovy 0.5mg side effects page. The STEP 1 trial, published in the New England Journal of Medicine, documented semaglutide 2.4mg's efficacy and safety profile across 68 weeks in a large population, the safety data from that trial is the foundation of what the NHS and MHRA guidance reflects.

If you've been on a lower dose and side effects have been manageable, reaching 2.4mg is usually achievable. If earlier doses caused significant problems, that's precisely the conversation to have before the next increase rather than after it. For context on the step just above this one (a higher maintenance dose approved more recently) the Wegovy 7.2mg side effects page covers that territory. And for the broader Wegovy picture, the Wegovy overview page brings together eligibility, evidence and access options in one place.

If you'd like to discuss your specific situation with a prescriber, a free consultation with our clinical team is the right starting point. Side effects and suitability are part of every conversation.